|
Main | | |
| Severin Schwan | CEO, Roche |
| Franz Humer | Chairman of Board, Roche |
| Erich Hunziker | CFO, Roche |
| Dan Zambrowski | Roche Head Pharma Partnering |
| Jean-Jacques Garaud | Roche Pharma Research and Early Development, Head of Pharma Development |
| Burkhard Piper | Roche Head of Diabetes Care |
| Gerd Maass | CEO of Roche NimbleGen |
| Richard Scheller | Genentech Research and Early Development |
| Varun Nanda | Roche Global Product Strategy Head of Oncology |
| Niko Andre | Roche Global Medical Director for Avastin |
| Stefan Frings | Roche Global HER2 Franchise Leader |
| Ian Clark | CEO, Genentech |
| | |
| | |
| | |
| | |
| | |
| Chugai Ownership?? | |
| 3/26/2009 acquired full ownership of Genentech. | |
| | |
| Departures | |
| Bill Burns | CEO of Pharma, Retired. |
| Pascal Soriot | Roche COO Pharma, became CEO of AZN. |
| Daniel O'Day | Roche COO Diagnostics, became CEO of GILD. |
| Sandra Horning | Genentech SVP, Global Head of Clinical Development in Hematology/Oncology, promoted to CMO/Head of Global Product Development |